

## Notice Concerning the Construction of a New Pharmaceutical Product Plant at Consolidated Subsidiary in Vietnam

Lion Corporation (President and Representative Director: Masayuki Takemori) hereby announces its decision to begin construction on a new pharmaceutical product plant at a subsidiary of Merap Lion Holding Limited Liability Company (hereinafter “Merap Lion”), a wholly owned subsidiary of Lion, in the Socialist Republic of Viet Nam (hereinafter “Vietnam”).

### 1. Reasons for Building the New Plant

To strengthen profitability, one of the core themes of the Vision2030 2nd STAGE medium-term management plan launched in 2025, the Lion Group is working to enhance its business portfolio management.

To this end, the Pharmaceuticals business has been positioned as a Challenge for Growth business, and the Company is working to create new business opportunities primarily overseas. As part of these efforts, in July 2025, Lion acquired Merap Lion, a pharmaceutical company based in Vietnam where economic growth continues to be strong in Southeast Asia, and made it a wholly owned subsidiary.

Merap Lion possesses strong pharmaceutical brands whose main dosage forms are liquid formulations such as nasal sprays and eyedrops, as well as a nationwide distribution network and high sales capabilities. Leveraging these strengths, the decision has been made to construct a new plant for solid dosage forms (tablets and granules) in order to expand the company’s highly profitable pharmaceutical business.

By broadening the product lineup and increasing production capacity, we will contribute to the healthcare of consumers in Vietnam while also working to further strengthen profitability in the country.

### 2. Overview of the New Plant

(1) Location	Hung Yen Province, Vietnam
(2) Lot size	2,660 m <sup>2</sup>
(3) Total floor area	7,172 m <sup>2</sup>
(4) Main products	Pharmaceutical products (prescription and OTC drugs)
(5) Investment scale	250,000 million VND (approx. ¥1.5 billion)
(6) Construction start date (tentative)	October 2026
(7) Operations start date (tentative)	Second half of 2030

Note: The above are plans that are still in consideration and thus subject to change. Funds for this investment will be allocated from the subsidiary’s cash reserves.

### 3. Overview of Merap Lion

(1) Name	Merap Lion Holding Limited Liability Company
(2) Location	Ho Chi Minh City, Vietnam
(3) Representative	Kazuo Mabuchi
(4) Business	Strategic and operational management of Merap group companies involved mainly in the manufacture and sale of pharmaceuticals and medical devices
(5) Capital	224,000 million VND (approx. ¥1.4 billion)
(6) Date of establishment	June 3, 2019
(7) Major shareholders and shareholding ratios	Lion: 100%
(8) Major consolidated subsidiary	Merap Group Corporation Representative: Phan Thi Thanh Thuy Business: Manufacture and sale of pharmaceuticals and medical devices etc. Shares held: 100%

### 4. Impact on Business Performance

The impact of this project on the consolidated results of the Lion Group has already been factored into the forecast for the fiscal year ending December 31, 2026.

Reference: Rendition of the completed new plant



Main Products of Merap Lion (As of June 30, 2026)



XISAT  
Nasal Spray



MESECA  
Nasal Spray  
\*Prescription drug



OSLA  
Eyedrop (artificial tears)



EBYSTA  
Gastrointestinal Drug

### Related Information

- [Notice Concerning the Acquisition of Shares of an Equity-Method Affiliate in Vietnam](#) (April 17, 2025)
- [Merap Lion](#) (Merap Lion Official Website)